Gyeonggi-do, South Korea

Keonseung Lim

USPTO Granted Patents = 7 


Average Co-Inventor Count = 9.1

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020-2023

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Keonseung Lim: Innovator in Biotherapeutics

Introduction

Keonseung Lim is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biotherapeutics, holding a total of 7 patents. His work focuses on developing innovative compounds for the treatment of various medical disorders.

Latest Patents

One of his latest patents is titled "Substituted indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors." This patent provides a compound of Formula (I) or pharmaceutically acceptable salts, along with a composition comprising the compound. It also outlines methods for using the compound to treat disorders associated with HPK1 and methods for preparing these compounds. Another notable patent is "Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders." This patent details a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers, and a pharmaceutical composition. It also describes a method to treat or prevent neurodegenerative diseases using the compound.

Career Highlights

Keonseung Lim is currently associated with 1st Biotherapeutics, Inc., where he continues to advance his research and development efforts. His innovative approach has positioned him as a key player in the biotherapeutics industry.

Collaborations

He collaborates with talented individuals such as Jinhwa Lee and Suyeon Jo, contributing to a dynamic research environment that fosters innovation.

Conclusion

Keonseung Lim's work in biotherapeutics exemplifies the impact of innovation in medicine. His patents reflect a commitment to addressing critical health challenges through scientific advancement.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…